Cambridge Investment Research Advisors, Inc. Viking Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 13,566 shares of VKTX stock, worth $514,422. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,566
Previous 29,721
54.36%
Holding current value
$514,422
Previous $718,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding VKTX
# of Institutions
452Shares Held
67.9MCall Options Held
7.72MPut Options Held
3.25M-
Vanguard Group Inc Valley Forge, PA10.2MShares$385 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$229 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$143 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.25MShares$123 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$119 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.91B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...